HLS Therapeutics's purchase of property, plant, equipment for the
three
months ended in Mar. 2026 was C$0.00 Mil. It means HLS Therapeutics spent C$0.00 Mil on purchasing property, plant, equipment.
HLS Therapeutics's purchase of property, plant, equipment for the trailing twelve months (TTM) ended in Mar. 2026 was C$-0.25Mil.
Compared with last quarter (C$-0.05 Mil in Dec. 2025 ), HLS Therapeutics spent less money on purchasing property, plant, equipment in Mar. 2026 (C$0.00 Mil).
HLS Therapeutics Purchase Of Property, Plant, Equipment Related Terms
HLS Therapeutics Purchase Of Property, Plant, Equipment Historical Data
* Premium members only.
The historical data trend for HLS Therapeutics's Purchase Of Property, Plant, Equipment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HLS Therapeutics Purchase Of Property, Plant, Equipment Chart
HLS Therapeutics Purchase Of Property, Plant, Equipment Calculation
The amount used to purchase PPE.
Purchase Of Property, Plant, Equipment for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-0.25 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Purchase Of Property, Plant, Equipment of C$-0.25 Mil mean?
HLS Therapeutics (TSX:HLS) has a Purchase Of Property, Plant, Equipment of C$-0.25 Mil as of Mar. 2026. Purchase of PP&E is the total purchase of property, plant and equipment. View historical data for HLS Therapeutics and its competitors.
Is HLS Therapeutics' Purchase Of Property, Plant, Equipment too high?
HLS Therapeutics' current Purchase Of Property, Plant, Equipment is C$-0.25 Mil. Overall, HLS Therapeutics has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' Purchase Of Property, Plant, Equipment compare to ZTS?
HLS Therapeutics' Purchase Of Property, Plant, Equipment of C$-0.25 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Purchase Of Property, Plant, Equipment for a Drug Manufacturers company?
A good Purchase Of Property, Plant, Equipment depends on the Drug Manufacturers industry context. However, Purchase Of Property, Plant, Equipment should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Purchase Of Property, Plant, Equipment mean?
A high Purchase Of Property, Plant, Equipment can signal that a stock is expensive relative to its fundamentals. Purchase of PP&E is the total purchase of property, plant and equipment. View historical data for HLS Therapeutics and its competitors. HLS Therapeutics's current Purchase Of Property, Plant, Equipment is C$-0.25 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.46, compared to a current price of C$4.42 — trading 0.9% below its estimated fair value. The current Purchase Of Property, Plant, Equipment is C$-0.25 Mil. HLS Therapeutics' overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Purchase Of Property, Plant, Equipment calculated?
Purchase Of Property, Plant, Equipment is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current Purchase Of Property, Plant, Equipment is C$-0.25 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?
Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued.
The current stock price of C$4.42 is trading 0.9% below its estimated GF Value™ of C$4.46.
GuruFocus considers HLS Therapeutics to be Fairly Valued.
Key valuation signals for TSX:HLS:
Purchase Of Property, Plant, Equipment: C$-0.25 Mil
GF Value™: C$4.46 vs. price of C$4.42 (0.9% below fair value)
No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
62GF Score
Get the complete analysis for TSX:HLS
Purchase Of Property, Plant, Equipment is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:HLS has been successfully added to your 
